Claes Wahlestedt

Last updated

Claes Wahlestedt is a Swedish-American biomedical researcher and entrepreneur. He is a professor at the University of Miami. [1]

Contents

Research

He is the inventor of the so-called AntagoNAT oligonucleotide technology, which allows for upregulation of genes in genetic and other disorders. [2] [3] A number of small molecule drugs have also been discovered by or under Wahlestedt's direction. [4] [5]

Career

He was a founding faculty member and director of neuroscience research at the Florida campus of The Scripps Research Institute (2005-2011). [6] In recent years he has co-founded several biotechnology companies, including CuRNA Inc., which was acquired by OPKO Health in 2011, [7] Epigenetix Inc. and Jupiter Orphan Therapeutics. [8]

References

  1. ↑ "Claes Wahlestedt, M.D., Ph.D." University of Miami Health System.
  2. ↑ "Anti-Antisense Makes Sense". Zone in With Zon. 23 February 2016.
  3. ↑ Rusk, Nicole (27 April 2012). "Gene expression: AntagoNATs boost gene expression". Nature Methods. 9 (5): 437. doi: 10.1038/nmeth.2007 . PMID   22803202. S2CID   28657529.
  4. ↑ "Alcohol Dependent People May Lack Important Enzyme". Neuroscience News. 4 September 2016.
  5. ↑ Pounds, Marcia Heroux (2 December 2016). "Gene analysis lab moves to Deerfield Beach". Sun-Sentinel.com.
  6. ↑ "Noted Swedish Scientist to Join Scripps Florida Faculty". Scripps Research. March 1971.
  7. ↑ Ostrowski, Jeff. "Jupiter-based Scripps spinoff cuRNA sells for $10 million". The Palm Beach Post.
  8. ↑ "Drug Discovery Pioneer and Biotech Entrepreneur Joins Miller School Faculty and Leadership". University of Miami.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.